These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 5585096)

  • 1. [First clinical experiences with ultrahigh single doses of cyclophosphamide].
    Schmitz G; Gross R
    Med Welt; 1967 Apr; 16():985-9. PubMed ID: 5585096
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of disulfiram on cyclophosphamide toxicity: a clinical trial.
    Ershler WB; Hacker MP; Newman RA; Stewart JA; Gamelli RL; Krakoff IH
    Cancer Treat Rep; 1983 Dec; 67(12):1145-7. PubMed ID: 6652633
    [No Abstract]   [Full Text] [Related]  

  • 3. [On clinical use of high single doses of sarcolysine and exdoxan (cyclophosphan)].
    Garin AM; Astrakhan VI; Bychkov MB; Larionov LF; Perevodchikova NI
    Vopr Onkol; 1965; 11(10):3-9. PubMed ID: 5333877
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical trial with fractionated high doses of cyclophosphamide].
    Macchiavelli M; Leone BA; Romero A; Rabinovich MG; Pérez JE
    Medicina (B Aires); 1986; 46(4):475-6. PubMed ID: 3574114
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of nandrolone phenylpropionate (Durabolin) on the bone-marrow suppression caused by cyclophosphamide.
    Cooke WM; Burn JI
    Br J Surg; 1971 Apr; 58(4):302-3. PubMed ID: 4929363
    [No Abstract]   [Full Text] [Related]  

  • 6. Intensive cyclophosphamide therapy in advanced malignant disease.
    Binns JH; Southall AC
    Practitioner; 1970 Apr; 204(222):546-8. PubMed ID: 5443539
    [No Abstract]   [Full Text] [Related]  

  • 7. [Results with cyclophosphamide therapy in single and massive dosage].
    Helbig W; Mühl H
    Z Gesamte Inn Med; 1967 Dec; 22(24):811-4. PubMed ID: 5585478
    [No Abstract]   [Full Text] [Related]  

  • 8. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Toxicity and side effects of cyclophosphamide].
    García Dadoni L; Rafael Seoane M
    Rev Clin Esp; 1968 Apr; 109(1):11-6. PubMed ID: 5738821
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.
    Sessa C; Pagani O; Parma G; Goldhirsch A; Cavalli F
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):112-7. PubMed ID: 7541152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The leucocyte nadir, a predictor of chemotherapy efficacy?
    Kvinnsland S
    Br J Cancer; 1999 Aug; 80(11):1681. PubMed ID: 10468282
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclophosphamide therapy of peripheral uveitis.
    Buckley CE; Gills JP
    Arch Intern Med; 1969 Jul; 124(1):29-35. PubMed ID: 5791483
    [No Abstract]   [Full Text] [Related]  

  • 13. [Results obtained by high doses of cyclophosphamide in solid tumors].
    Bilge N; Aran M
    Turk Tip Cemiy Mecm; 1970 Feb; 36(2):116-27. PubMed ID: 5502530
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses.
    Bergsagel DE; Robertson GL; Hasselback R
    Can Med Assoc J; 1968 Mar; 98(11):532-8. PubMed ID: 5643297
    [No Abstract]   [Full Text] [Related]  

  • 15. [Experience with high dosage cytostatic "high single dose" therapy of malignant tumors].
    Zerna M; Wolff H
    Bruns Beitr Klin Chir (1971); 1966 Mar; 212(2):146-53. PubMed ID: 5994826
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I clinical study of a static magnetic field combined with anti-neoplastic chemotherapy in the treatment of human malignancy: initial safety and toxicity data.
    Salvatore JR; Harrington J; Kummet T
    Bioelectromagnetics; 2003 Oct; 24(7):524-7. PubMed ID: 12955758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Limits and possibilities of cytostatic therapy with massive doses of cyclophosphamide].
    Chiarelli G; Garutti GP; Rambaldi P
    Arcisp S Anna Ferrara; 1967; 20(3):385-400. PubMed ID: 5606860
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
    Kligerman MM; Blumberg AL; Glick JH; Nelson DF; Glover D; Yuhas JM; Amols HI; Goodman RL
    Cancer Clin Trials; 1981; 4(4):469-74. PubMed ID: 6274534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Compatibility and action of very high dosage of endoxuan in the treatment of tumors].
    Martini H; Scheef W; Knecht B
    Med Welt; 1967 Jul; 26():1573-8. PubMed ID: 5616188
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experiences with the endoxan intensive therapy of malignant tumors].
    Gebhardt KH; Becher R
    Med Welt; 1966 Apr; 17():973-6. PubMed ID: 5985776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.